With the recent progress of mechanism-targeting therapies for PD, such as those targeting the propagation of α-synuclein using immunotherapeutic approaches into early human clinical trials [4], there is a pressing need for easily accessible molecular biomarkers that could track or predict disease progression in patients with PD. Here, SNCA is linked to Parkinson disease.